×
  • Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

by on Jun 25, 2013

  • 550 views

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the ...

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China, and India
Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes

Statistics

Views

Total Views
550
Views on SlideShare
550
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via SlideShare as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 Document Transcript